Profound Medical Corp. Announces Co-Marketing Agreement with Siemens Healthineers

Revolutionizing Prostate Therapy with TULSA-PRO® and Magnetom Free.Max

Profound Medical Corp. and Siemens Healthineers have come together in a groundbreaking co-sales and co-marketing agreement to introduce a new MRI-guided prostate therapy solution. This innovative solution combines Profound’s TULSA-PRO® system with Siemens Healthineers’ Magnetom Free.Max magnetic resonance scanner, enhancing the accuracy and precision of prostate cancer diagnosis, treatment, and follow-up.

Benefits of the TULSA-PRO® System

The TULSA-PRO® system utilizes real-time MR guidance to perform the Transurethral Ultrasound Ablation procedure, a minimally invasive treatment that preserves patients’ urinary continence and sexual function. By gently heating targeted prostate tissue to a precise temperature, TULSA-PRO® effectively ablates whole or partial-gland tissue in patients with various prostate conditions, including prostate cancer and benign prostatic hyperplasia.

This partnership between Profound Medical Corp. and Siemens Healthineers aligns with the CMS 2025 Final Rule, which establishes Urology APC Level 7 reimbursement for the TULSA procedure at all three sites of service. This means that patients can receive this advanced treatment with the support of their healthcare providers.

Impact on Individuals

For individuals seeking treatment for prostate cancer or other prostate conditions, the collaboration between Profound Medical Corp. and Siemens Healthineers offers a promising new option. The TULSA-PRO® system combined with the Magnetom Free.Max MR scanner provides a more accurate and precise treatment pathway, leading to better outcomes and improved quality of life for patients.

Global Impact

On a global scale, the introduction of this new prostate therapy solution has the potential to revolutionize the way prostate conditions are diagnosed and treated. By combining cutting-edge technology from two industry leaders, Profound Medical Corp. and Siemens Healthineers, healthcare providers worldwide can offer patients a more effective and efficient treatment option for prostate-related issues.

Conclusion

The partnership between Profound Medical Corp. and Siemens Healthineers represents a significant advancement in prostate therapy technology. By combining the TULSA-PRO® system with the Magnetom Free.Max MR scanner, patients can benefit from a more accurate and precise treatment approach. This collaboration has the potential to shape the future of prostate cancer treatment and improve outcomes for patients around the world.